Oral Ulcer Due to Benign Mucous Membrane Pemphioid Clinical Trial
Official title:
Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers
PRF in orabase will be applied as a pack material on chronic oral ulcers of chronic multiple oral lesions compared to conventional topical steroid therapy with clobetasol propionate 0.05% in orabase. The outcomes measured are Pain alleviation as Primary outcome and Clinical improvement in terms of Ulcer size, Number and Mucositis score as Secondary outcomes. Time frame for outcomes assessment will be Daily for 7 Days regarding pain score and weekly for 2 weeks regarding clinical improvement.
The management of oral ulcers and mucositis specially the resistant types such as oral ulcers
due to auto-immune diseases is a major concern by the dentists through all the world. Topical
corticosteroids, analgesics, Laser bio modulation all have been proposed as treatments with
limited efficacy in many cases. There are few number of clinical trials on Plasma preparation
in management of oral mucositis and oral ulcers. Platelet rich fibrin (PRF) is one of the
platelet concentrates. The preparation protocol of PRF is simple and easy, could be prepared
autologous and immediately placed on the oral ulcers and mucositis.
Subjects and Methods: A non Randomized clinical trial will be conducted. Ten patients with
different resistant oral ulcers and mucositis were enrolled. all with grade 4 WHO mucositis
score. The initial numerical ratting score of pain is 10. For all patients 20 ml blood sample
will obtained in plain blood vacutainer, centrifuged for 15 minutes on 3000 rpm. The
resultant gel, obtained and squeezed to prepare a membrane, the membrane will be mixed with
orabase and placed over the oral ulcers and mucositis over a piece of gauze. The patients
will be instructed not to eat or drink for 2 hours after application. The remaining serum
after squeezing was mixed with equal amount of orabase and used topically on the oral
mucositis and ulcers.
Clobetasol Propionate 0.05% in orabase will be applied to 10 control patients 3 times per day
for one week.
The steps will be repeated after one week if the patients' symptomatic scores for WHO and
numerical rating score were not zero.
;